Overview

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to evaluate the efficacy, safety and tolerability of the study medicine, volixibat, in patients with Intrahepatic cholestasis of pregnancy (ICP) and elevated serum bile acid concentrations.

Phase:

Phase 2

Details

Lead Sponsor:

Mirum Pharmaceuticals, Inc.

Treatments:

Volixibat